Intramyocardial immunomodulation with human CD16⁺ monocytes to treat myocardial infarction in pig: a blind randomized preclinical trial.

ABSTRACT:

Background

Human CD16⁺ monocytes (hCD16⁺ Ms) have proangiogenic properties. We assessed the feasibility, safety and efficacy of hCD16⁺ Ms in a porcine model of myocardial infarction (MI).

Methods and results

A total of 27 female Large White pigs underwent MI with reperfusion and cardiac magnetic resonance (CMR). Five days later, animals received intramyocardial injections of hCD16⁺ Ms in saline (n = 13) or saline only (n = 14). hCD16⁺ Ms were selected from leucocyte cones. Feasibility/safety endpoints included injury at injected sites, malignant arrhythmias, cancer, haematoma, left ventricular (LV) dilatation, troponin release and downstream organ injury. Co-primary efficacy outcome included LV scar and eje

SUBMITTER: Ascione R 

PROVIDER: S-EPMC11335517 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature